hapabapa
UBS has upgraded Roche (OTCQX:RHHBY) to buy from neutral, citing the company’s growth outlook.
“We see sustained outperformance of Vabysmo and Ocrevus as key drivers of near-term growth, with additional benefit from Xolair food allergy and potential upside from Elevidys ex-US,” UBS